Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ISAAC LEVY

NPI
1871577221
CMS profile
312330
Location
PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$15,269.47

235 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $7,531.23 12
E.R. Squibb & Sons, L.L.C. $2,169.60 13
PFIZER INC. $1,975.21 39
Janssen Biotech, Inc. $487.67 23
AstraZeneca Pharmaceuticals LP $283.93 12
GlaxoSmithKline, LLC. $244.95 10
Novartis Pharmaceuticals Corporation $242.35 12
Merck Sharp & Dohme LLC $181.97 9
Eisai Inc. $167.76 9
Takeda Pharmaceuticals U.S.A., Inc. $145.58 8
Lilly USA, LLC $130.27 7
Alexion Pharmaceuticals, Inc. $125.68 4
Rigel Pharmaceuticals, Inc. $116.66 5
Daiichi Sankyo Inc. $111.43 5
Regeneron Healthcare Solutions, Inc. $97.07 4
SOBI, INC $93.44 5
PharmaEssentia USA Corporation $90.31 5
Ipsen Biopharmaceuticals, Inc $80.37 4
Myriad Genetic Laboratories, Inc. $76.51 3
ABBVIE INC. $72.22 4
Incyte Corporation $70.07 3
Karyopharm Therapeutics Inc. $62.50 2
Exelixis Inc. $56.01 4
Sumitomo Pharma America, Inc. $51.15 2
ARRAY BIOPHARMA INC $45.33 4
Fennec Pharmaceuticals, Inc. $43.83 2
TAIHO ONCOLOGY, INC. $40.14 2
Amneal Pharmaceuticals LLC $39.93 2
Bayer Healthcare Pharmaceuticals Inc. $39.88 2
Celgene Corporation $38.96 2
Janssen Scientific Affairs, LLC $37.87 1
EMD Serono, Inc. $36.65 2
Blueprint Medicines Corporation $36.63 2
Kite Pharma, Inc. $33.92 1
Janssen Pharmaceuticals, Inc $25.72 1
Pharmacosmos Therapeutics Inc. $24.81 1
TerSera Therapeutics LLC $22.18 1
Mirati Therapeutics, Inc. $21.28 1
BeiGene USA, Inc. $20.02 1
SERVIER PHARMACEUTICALS LLC $19.32 1
Gilead Sciences, Inc. $18.72 1
Adaptive Biotechnologies Corporation $17.74 1
Tempus AI, Inc $15.54 1
SUN PHARMACEUTICAL INDUSTRIES INC. $13.92 1
RECORDATI_RARE_DISEASES_INC. $13.14 1

Page 5 of 5; records 201–235 of 235 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ISAAC LEVY

NPI 1871577221 · CMS profile ID 312330

PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–235 of 235 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871577221?year=2024&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ISAAC LEVY, NPI 1871577221, CMS profile ID 312330. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–235 of 235 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871577221?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ISAAC LEVY, NPI 1871577221, CMS profile ID 312330. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–235 of 235 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871577221?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ISAAC LEVY, NPI 1871577221, CMS profile ID 312330, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–235 of 235 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1871577221?year=2024&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

235 matching records · $15,269.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 235 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–235 of 235.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $17.9002/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120226465 CMS
Lilly USA, LLC $22.0002/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135012667 CMS
Rigel Pharmaceuticals, Inc. $29.5302/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145199358 CMS
E.R. Squibb & Sons, L.L.C. $17.3202/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101211044 CMS
E.R. Squibb & Sons, L.L.C. $1,880.0002/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101211030 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.1202/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144961678 CMS
Mirati Therapeutics, Inc. $21.2802/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117159744 CMS
PFIZER INC. $27.2202/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131192984 CMS
PFIZER INC. $39.9902/07/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131516472 CMS
PFIZER INC. $39.9902/07/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131556640 CMS
Eisai Inc. $1.4302/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110749728 CMS
Eisai Inc. $22.4802/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110749722 CMS
E.R. Squibb & Sons, L.L.C. $30.0002/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101211090 CMS
E.R. Squibb & Sons, L.L.C. $50.0002/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101211092 CMS
E.R. Squibb & Sons, L.L.C. $64.9902/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101211094 CMS
Incyte Corporation $22.6302/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141283481 CMS
Tempus AI, Inc $15.5402/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150168514 CMS
Eisai Inc. $25.6601/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110749724 CMS
Lilly USA, LLC $16.9501/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135010299 CMS
Regeneron Healthcare Solutions, Inc. $15.2801/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114099986 CMS
Novartis Pharmaceuticals Corporation $21.8201/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087052172 CMS
AstraZeneca Pharmaceuticals LP $29.4001/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110546329 CMS
GlaxoSmithKline, LLC. $20.7301/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116620981 CMS
Adaptive Biotechnologies Corporation $17.7401/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150260988 CMS
Janssen Biotech, Inc. $22.5001/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078425076 CMS
PharmaEssentia USA Corporation $13.4601/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137311296 CMS
GENZYME CORPORATION $31.7201/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139632921 CMS
Novartis Pharmaceuticals Corporation $21.1101/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087052134 CMS
Rigel Pharmaceuticals, Inc. $33.7201/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145199360 CMS
SOBI, INC $22.0401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141415494 CMS
PFIZER INC. $19.2101/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131169198 CMS
Regeneron Healthcare Solutions, Inc. $31.4901/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114099984 CMS
TAIHO ONCOLOGY, INC. $21.6701/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137935835 CMS
Amneal Pharmaceuticals LLC $19.4001/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139193116 CMS
Myriad Genetic Laboratories, Inc. $19.5401/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152535035 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,870.38 182
PY2020 $4,394.75 158
PY2021 $7,365.04 184
PY2022 $7,991.97 193
PY2023 $5,942.90 209
PY2024 $15,269.47 235
PY2025 $4,929.44 193

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $14,203.00 1
PY2025 Principal investigator $754,791.33 11
PY2024 Principal investigator $285,056.92 11
PY2023 Recipient $725.51 1
PY2023 Principal investigator $171,602.12 12
PY2022 Recipient $23.00 1
PY2022 Principal investigator $642,217.99 20
PY2021 Recipient $609.00 1
PY2021 Principal investigator $340,384.50 22
PY2020 Recipient $10.86 1
PY2020 Principal investigator $558,222.57 17
PY2019 Recipient $1,731.80 2
PY2019 Principal investigator $525,658.72 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $176,853.69 12/18/2025 Non-covered Recipient Entity
MILLENNIUM ONCOLOGY RESEARCH CLINIC ISAAC LEVY MD PA
A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study No dispute reported 06/30/2026 1190311521
Principal investigator 1 GENZYME CORPORATION $22,534.00 12/12/2025 Non-covered Recipient Entity
Millennium Oncology Research Clinic Inc
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226108213
Principal investigator 1 Karyopharm Therapeutics Inc. $3,114.00 11/12/2025 Non-covered Recipient Entity
Millen Dialysis Clinic LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664190
Principal investigator 1 Karyopharm Therapeutics Inc. $7,782.00 09/26/2025 Non-covered Recipient Entity
Millen Dialysis Clinic LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664188
Principal investigator 1 SANOFI US SERVICES INC. $650.00 07/11/2025 Non-covered Recipient Entity
Millennium Oncology Research Clinic Inc
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226097751
Principal investigator 1 Karyopharm Therapeutics Inc. $7,782.00 06/16/2025 Non-covered Recipient Entity
Millen Dialysis Clinic LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664184
Principal investigator 1 Amgen Inc. $11,478.80 06/01/2025 Non-covered Recipient Entity
MILLENNIUM ONCOLOGY RESEARCH CLINIC
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1246644721
Recipient GENZYME CORPORATION $14,203.00 04/28/2025 Covered Recipient Physician A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226102328
Principal investigator 1 Karyopharm Therapeutics Inc. $16,712.00 03/31/2025 Non-covered Recipient Entity
Millen Dialysis Clinic LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664186
Principal investigator 1 Novartis Pharmaceuticals Corporation $494,845.04 03/31/2025 Non-covered Recipient Entity
MILLENNIUM ONCOLOGY RESEARCH CLINIC ISAAC LEVY MD PA
A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study No dispute reported 06/30/2026 1190311523
Principal investigator 1 Eli Lilly and Company $12,112.00 02/11/2025 Non-covered Recipient Entity
MILLENNIUM ONCOLOGY RESEARCH CLINIC DBA ISAAC LEVY
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187884646
Principal investigator 1 Eli Lilly and Company $927.80 01/09/2025 Non-covered Recipient Entity
MILLENNIUM ONCOLOGY RESEARCH CLINIC DBA ISAAC LEVY
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187885508